FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 05:25:56 2024-06-21 EDT | ||
| 15.25 EUR | -1.49% |
|
| Current month | -5.15% | ||
| 1 month | +32.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 15.25 | -1.49% |
| 24-06-20 | 15.48 | -1.71% |
| 24-06-19 | 15.75 | -10.66% |
| 24-06-18 | 17.63 | +13.09% |
| 24-06-17 | 15.59 | +6.13% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 05:25 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SF3B3P |
| ISIN | DE000SF3B3P3 |
| Date issued | 2021-08-09 |
| Strike | 68.4 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.42 € |
|---|---|
| Lowest since issue | 0.95 € |
| Spread | 0.46 € |
| Spread % | 2.93% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.04
USD
Average target price
53.19
USD
Spread / Average Target
+29.62%
- Stock Market
- Certificates
- Certificat
